Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
12 hedge funds and large institutions have $127K invested in Baudax Bio, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
74% more capital invested
Capital invested by funds: $73.2K → $127K (+$53.9K)
20% more funds holding
Funds holding: 10 → 12 (+2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$83.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$63.3K |
| 3 |
JP Morgan Chase
New York
|
+$3.84K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.17K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.57K |
| 3 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$226 |
| 4 |
Morgan Stanley
New York
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $55.8K | +$83.5K | +32,812 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $42.3K | +$63.3K | +24,900 | New |
|
|
3
State Street
Boston,
Massachusetts
| $19.7K | -$18.3K | -7,200 | -38% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $3K | +$3.17K | +1,247 | +414% |
|
|
5
JP Morgan Chase
New York
| $3K | +$3.84K | +1,511 | New |
|
|
6
Fidelity Investments
Boston,
Massachusetts
| $1.79K | +$2.69K | +1,056 | New |
|
7
BlackRock
New York
| $1.35K | – | – | – |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $35 | – | – | – |
|
9
Group One Trading
Chicago,
Illinois
| $7 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $5 | – | – | – |
|
|
11
Morgan Stanley
New York
| $2 | -$3 | -1 | -50% |
|
|
SN
12
Sittner & Nelson
Eugene,
Oregon
| $2 | – | – | – |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$9.57K | -3,011 | Closed |
|
|
EDRH
14
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$226 | -71 | Closed |
|
BXRX Hedge Fund Activity: Q1 2023 in Review
12 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q1 2023, worth a combined $127K — up 74% from $73.2K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BXRX positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $83.5K. The largest seller was State Street, cutting an estimated $18.3K.
- 12 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q1 2023, up from 10 in Q4 2022.
- Funds reported $127K of Baudax Bio, Inc. Common Stock stock for Q1 2023, up 74% quarter-over-quarter.
- 4 funds opened new Baudax Bio, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q1 2023 was Susquehanna International Group, an estimated $83.5K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q1 2023 was State Street, an estimated $18.3K sold.
Based on aggregated 13F filings for Q1 2023.